Sykehuset Telemark
Skien, Norway
2 recruiting
Showing 1–3 of 3 trials
Recruiting
Phase 2Phase 3
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
Atherosclerotic Cardiovascular Disease in Patients With ESKD
CSL Behring3,110 enrolled547 locationsNCT05485961
Recruiting
DESTINY Breast Respond HER2-low Europe
Metastatic Breast CancerUnresectable Breast CancerHER2-low Expressing Breast Cancer
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company1,155 enrolled211 locationsNCT05945732
Recruiting
Phase 2
Improving Public Cancer Care by Implementing Precision Medicine in Norway
Cancer, Metastatic
Oslo University Hospital3,000 enrolled17 locationsNCT04817956